Heart 94:311-315 doi:10.1136/hrt.2007.115626
  • Original research
  • Coronary artery disease

Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation

  1. J Sanchis1,
  2. X Bosch2,
  3. V Bodí1,
  4. N Bellera2,
  5. J Núñez1,
  6. B Benito2,
  7. J Ordóñez3,
  8. L Consuegra1,
  9. M Heras2,
  10. À Llècer1
  1. 1
    Servei de Cardiologia, Hospital Clínic Universitari, Universitat de València, València, Spain
  2. 2
    Servei de Cardiologia, Hospital Clínic i Provincial, Barcelona, Spain
  3. 3
    Departament de Bioquímica, Hospital de la Santa Creu i San Pau, Barcelona, Spain
  1. Dr J Sanchis, Servei de Cardiologia, Hospital Clinic Universitari, Blasco Ibáñez 17, 46010 València, Spain; sanchis_juafor{at}
  • Accepted 23 May 2007
  • Published Online First 16 July 2007


Objective: To investigate the combination of clinical data, exercise testing and biomarkers for the evaluation of patients with chest pain without ST-segment deviation or troponin elevation.

Design: Prospective cohort design.

Settting: Two teaching hospitals in Spain.

Patients: 422 patients presenting to the emergency department were studied. Leukocyte count, C-reactive protein (CRP), pregnancy-associated plasma protein A (PAPP-A) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were determined. A validated clinical risk score (number of points according to pain characteristics and risk factors) was used for clinical evaluation and early exercise testing was performed.

Main outcome measures: Adverse events (death, myocardial infarction or revascularisation) during a median 60 weeks follow-up.

Results: By receiver operating characteristic curve analysis, the association between death or myocardial infarction and adverse events was not significant with leukocyte count (p = 0.3, p = 0.3) or CRP (p = 0.5, p = 0.8), was borderline significant with PAPP-A (p = 0.07, p = 0.04) and strongly significant with NT-pro-BNP (p = 0.0001, p = 0.0001). By Cox regression including clinical risk score, exercise testing result and biomarkers, exercise testing was the independent predictor of revascularisation (p = 0.0001), whereas risk score (p = 0.03) and NT-proBNP (p = 0.0004) predicted death or myocardial infarction. The inclusion of NT-proBNP improved the accuracy of the model for death or myocardial infarction (C-statistic 0.84 versus 0.76, p = 0.01). The combination of clinical score and NT-proBNP afforded the stratification in high (17.2%, p = 0.0001), intermediate (5.3%) and low (1.1%) risk categories of death or myocardial infarction.

Conclusions: NT-proBNP provides incremental prognostic information above that given by clinical history and exercise testing in patients with chest pain without ST-segment deviation and negative troponin.


  • Funding: This work was supported by a grant Pfizer-2004 from the Spanish Society of Cardiology (Madrid, Spain) and a grant from HERACLES-FIS (Ministerio de Sanidad y Consumo, Madrid, Spain). JS, VB, JN and AL were also supported by a grant FIS PI070640 (Ministerio de Sanidad y Consumo, Madrid, Spain) and XB was supported by a grant FIS PI0500120 (Ministerio de Sanidad y Consumo, Spain).

  • Competing interests: None declared.